ODN 2088 | Unit size | Cat. code | Docs | Price |
---|---|---|---|---|
TLR9 antagonist - Mouse preferred | 200 µg 1 mg 5 mg | tlrl-2088 | TDSMSDS | Please contact our distributor Add to favorite |
Toll-like receptor 9 (TLR9) recognizes specific unmethylated CpG oligonucleotide (ODN) sequences that distinguish microbial DNA from mammalian DNA.
Studies suggest the existence of DNA sequences that can neutralize the stimulatory effect of CpG ODNs [1].
These sequences are characterized by three consecutive Gs downstream of a C or A, addition of a fourth G (G-tetrads) increases the inhibitory capability.
The most potent inhibitory sequences are (TTAGGG)4 found in mammalian telomeres [2] and ODN 2088 which derives from a stimulatory ODN by replacement of 3 bases [3].
Inhibitory ODNs act by disrupting the colocalization of CpG ODNs with TLR9 in endosomal vesicles without affecting cellular binding and uptake.
References:
1. Krieg AM. et al., 1998. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci USA. 95(21): 12631-6.2. Gursel I. et al., 2003. Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J Immunol. 171(3):1393-400.3. Stunz LL. et al., 2002. Inhibitory oligodinucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. Eur J Immunol. 32(5): 1212-22.
Back to the topSpecificity: murine TLR9 antagonist
Working concentration: 100 nM - 10 µM
Solubility: 2.5 mg/ml in water
ODN 2088 sequence5’- tcc tgg cgg gga agt -3’ (15 mer)Note: Bases are phosphorothioate (nuclease resistant).
Quality control:
ODN 2088 is provided lyophilized and is available in three quantities:
ODN 2088 is shipped at room temperature.
Upon receipt, store at -20 °C.
Back to the top2018 Diabetologia. DOI: 10.1007/s00125-018-4705-0
Liu M. et al.
2018 Pathol Oncol Res DOI: 10.1007/s12253-018-0544-z
Sipos F. et al.
2018 Cells. DOI: 10.3390/cells8010003
Guo H.Y. & Cui Z.J.
2017 Front Immunol. 8:1039.
Auger JP. et al.
2017 Cell Physiol Biochem. 41(4):1547-1554.
Shao Z. et al.
2017 PLoS One. 12(1):e0169245.
Gahlot S. et al.
2016 Arthritis Res Ther. 18(1):264.
Lee JY. et al.
2016 Ann Rheum Dis. 75(10):1858-65.
Yoshizaki A. et al.
2015 FASEB J. ;29(2):684-95
Al-Nedawi K, Mian MF, Hossain N, Karimi K, Mao YK, Forsythe P, Min KK, Stanisz AM, Kunze WA, Bienenstock J.
2014 J Am Heart Assoc.3(2):e000629.
Lu C, Ha T, Wang X, Liu L, Zhang X, Kimbrough EO, Sha Z, Guan M, Schweitzer J, Kalbfleisch J, Williams D, Li C.
2011 Blood 117: 6459 - 6468
Martino A.T. et al.
2011 J. Immunol. 186: 6417 - 6426
Qi J, Buzas K, Fan H, Cohen JI, Wang K, Mont E, Klinman D, Oppenheim JJ, Howard OM
Load moreInvivogen
InvivoGen的主要重点是通过提供创新的研究工具,促进生命科学的进步。除了我们的先天免疫研究产品,我们利用在发酵和克隆方面的技术,提供高质量的抗生素和新型质粒。我们提供所有常见的抗生素和哺乳动物选择抗生素,以预防和消除所有类型的微生物污染物,包括支原体等。我们也是开发和销售无CpG质粒的唯一公司。我们为研究团体提供多种产品系列,涉及许多学科,包括RNA干扰,免疫球蛋白A,基因治疗和癌症研究。
InvivoGen was founded in 1997 by scientists with technical expertise and creative excellence stemming from a longstanding history in microbiology. InvivoGen's unparalleled skill in microbial fermentation enables us to provide a wide range of biological molecules, including ultra-pure antibiotics, novel mycoplasma treatments and the largest collection of pattern recognition receptor agonists derived from a wide range of micro-organisms.
In addition we boast strong chemistry and molecular biology teams for the synthesis of molecules and plasmids for research use and studies focused on gene therapy and vaccination. Moreover, our specialized study of the innate immune receptor signaling pathways has resulted in the collection of reporter cell lines, which are routinely used for in-house quality control and research and development.
产品列表:
Invivogen | ant-agl-25 | 17-AAG | 25 mg |
Invivogen | ant-agl-5 | 17-AAG | 5 mg |
Invivogen | ant-egl-1 | 17-AEP-GA | 1 mg |
Invivogen | ant-egl-5 | 17-AEP-GA | 5 mg |
Invivogen | ant-dgl-25 | 17-DMAG | 25 mg |
Invivogen | ant-dgl-5 | 17-DMAG | 5 mg |
Invivogen | ant-mgl-1 | 17-DMAP-GA | 1 mg |
Invivogen | ant-mgl-5 | 17-DMAP-GA | 5 mg |
Invivogen | gmbapa-ga | 17-GMB-APA-GA | 1 mg |
Invivogen | ant-nhgl-1 | 17-NHS-ALA-GA | 1 mg |
Invivogen | tlrl-nacda23 | 2'3'-c-di-AMP | 500 µg |
Invivogen | tlrl-25gpap | 2'3'-cGAMP Control | 1 mg |
Invivogen | tlrl-apr | 2-Aminopurine | 250 mg |
Invivogen | 293-hmd2cd14 | 293/hMD2-CD14 | 3-7 x 10e6 cells |
Invivogen | 293-hnod1 | 293/hNOD1 | 3-7 x 10e6 cells |
Invivogen | 293-hnod2 | 293/hNOD2 | 3-7 x 10e6 cells |
Invivogen | 293-htlr1ha | 293/hTLR1-HA | 3-7 x 10e6 cells |
Invivogen | 293-htlr10ha | 293/hTLR10-HA | 3-7 x 10e6 cells |
Invivogen | 293-htlr2 | 293/hTLR2 | 3-7 x 10e6 cells |
Invivogen | 293-htlr2cd14 | 293/hTLR2-CD14 | 3-7 x 10e6 cells |
Invivogen | 293-htlr2ha | 293/hTLR2-HA | 3-7 x 10e6 cells |
Invivogen | 293-htlr2/6 | 293/hTLR2-TLR6 | 3-7 x 10e6 cells |
Invivogen | 293-htlr3 | 293/hTLR3 | 3-7 x 10e6 cells |
Invivogen | 293-htlr3ha | 293/hTLR3-HA | 3-7 x 10e6 cells |
Invivogen | 293-htlr4ha | 293/hTLR4-HA | 3-7 x 10e6 cells |
Invivogen | 293-htlr4a | 293/hTLR4A | 3-7 x 10e6 cells |
Invivogen | 293-htlr4md2cd14 | 293/hTLR4A-MD2-CD14 | 3-7 x 10e6 cells |
Invivogen | 293-htlr5 | 293/hTLR5 | 3-7 x 10e6 cells |
Invivogen | 293-htlr5cd14 | 293/hTLR5-CD14 | 3-7 x 10e6 cells |
Invivogen | 293-htlr5ha | 293/hTLR5-HA | 3-7 x 10e6 cells |
Invivogen | 293-htlr6ha | 293/hTLR6-HA | 3-7 x 10e6 cells |
Invivogen | 293-lacz | 293/LacZ | 3-7 x 10e6 cells |
Invivogen | 293-mnod1 | 293/mNOD1 | 3-7 x 10e6 cells |
Invivogen | 293-mnod2 | 293/mNOD2 | 3-7 x 10e6 cells |